Zoptarelin Doxorubicin Shows Promise in Patients With Endometrial Cancer
Hybrid molecule consists of peptide carrier and chemotherapy agent (February 4)
Promising phase II data on zoptarelin doxorubicin (AEZS-108, Aeterna Zentaris) in endometrial cancer have been published in the February issue of the International Journal of Gynecological Cancer.
Forty-three women with advanced or recurrent luteinizing hormone-releasing hormone (LHRH) receptor-positive endometrial cancer were evaluated in a European study. Two patients (5%) experienced complete remission, and eight (18%) achieved partial remission. Stable disease for at least 6 weeks was observed in 19 patients (44%). The median time to progression was 7 months, and median overall survival was 15 months. The most frequently reported grade-3 or -4 adverse effects were neutropenia (12%) and leukopenia (9%).
Zoptarelin doxorubicin is a hybrid molecule consisting of a synthetic peptide carrier and a commonly used chemotherapy agent, doxorubicin. It is the first intravenous drug in advanced clinical development that directs the chemotherapy agent specifically to LHRH receptor-expressing tumors.
Endometrial cancer is the most common gynecologic malignancy in developed countries. The disease largely affects women over the age of 50 years, with a higher prevalence in Caucasians and a higher mortality rate in African-Americans. According to the American Cancer Society, an estimated 49,560 new cases of endometrial cancer were expected to occur in the U.S. in 2013.
Source: Aeterna Zentaris; February 4, 2014.